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Introduction
Results 144 145 Refining a rapid throughput assay for secreted HCV infectivity 146 p7 channel activity is essential for the secretion of infectious virions(20), making secreted 147 infectivity an ideal biomarker readout for inhibitor antiviral effects. To expedite testing of 148 secreted HCV infectivity following treatment with high numbers of compounds and/ or 149 concentration points, we adapted previously published protocols using the IncuCyte 150 ZOOM(34) to quantify infection of naïve cells immunostained for NS5A ( Fig 1A) . 151 Dilution of virus-containing supernatants was optimised (1:4) for signal-to-noise whilst 152 accurately reflecting infectivity (i.e. within the linear range of a dilution series correctly 153 determining virus titre, see Fig S1A) . This negates the need for serial dilutions and 154 removes both human error and the amplification of said error due to multiplication by 155 large dilution factors. The assay is applicable to multiple native or chimeric viruses and 156 readily generates 8-point IC 50 curves in a reporter-free system.
Identification of lead compound JK3/32
174 SAR-focused chemical modification (Table 1) of an oxindole core scaffold identified 175 "JK3/32" as a series lead with excellent potency against chimaeric genotype 1b HCV 176 (J4/JFH-1) secretion (IC 50~1 84 nM) ( Fig 1B, S1C) . Thus, JK3/32 potency was 177 comparable to SOF and considerably improved compared with the prototypic p7 inhibitor 178 (p7i), Rimantadine. As seen for first generation compounds(24), JK3/32 retained cross-179 genotype activity versus HCV genotype 3a (IC 50~7 38 nM), with a modest reduction in 180 activity against more genetically distant 2a viruses (IC 50~1 900 nM) ( Fig 1C) . The 181 compound showed a toxicity-based selectivity index of >500 (CC 50 > 100 000 nM based 182 upon confluency ( Fig S1C) and MTT assay ( Fig S2A) in Huh7 cells, and had no discernible effect upon replication of HCV JFH-1 subgenomic replicons, which retain the 184 same replicase as chimaeric viruses but lack the structural proteins, p7 and NS2 (Fig S2B) . 185 The oxindole scaffold of JK3/32 resembles that of certain licensed kinase inhibitor drugs 186 (Sunitinib, Nintedanib) . However, the JK series of inhibitors is chemically distinguished 187 from these compounds by an N-alkyl substituent, which was essential for anti-HCV 188 activity (Table 1) ; accordingly, JK3/32 displayed no off-target activity against a panel of 189 human kinases tested commercially ( Fig S2C) . 190 JK3/32 was part of a chemical series derived through evolution of an original hit 191 compound, LDS19, selected in silico using a 3ZD0-based structure model template (24) 192 ( Fig S3) . The first iteration of compounds (prefix "RS") was tested using in vitro dye 193 release assays(35) using genotype 1b p7 (J4 strain) ( Fig S4) . This confirmed that variation 194 of the prototypic scaffold generated compounds displaying activity versus p7 channel 195 function and that a specific structure-activity relationship (SAR) should be achievable. 196 Cell culture assays confirmed compound activity and comprised the screening method for 197 ensuing compound iterations (Table 1) . 198 Finally, we compared JK3/32 with an amiloride derivative that has been progressed into 199 early phase human trials in Asia. BIT225 was identified as an inhibitor of genotype 1a p7 200 using a bacterial screen and has been reported to display activity versus Bovine viral 201 diarrhoea virus (BVDV)(36), and more recently HCV in cell culture (37) . However, in our 202 hands BIT225 showed no antiviral activity discernible from effects upon cellular viability 203 ( Fig S5) ; notably, no assessment of cellular toxicity was undertaken during previously 204 reported HCV studies(37), which used a concentration higher (30 μM) than the observed 205 Huh7 CC 50 herein (18.6 μM) during short timescale assays (6-24 h). 206 207 JK3/32 SAR corroborates predicted binding to hairpin-based p7 channel models 208 We developed a library of JK3/32 analogues to explore SAR for inhibition of J4/JFH-1 209 secretion (Table 1) . Of forty-one compounds tested, twenty contributed directly to the 210 JK3/32 SAR, which was largely consistent with energetically preferred in silico docking 211 predictions (using Glide, Schrodinger). JK3/32 is predicted to bind into a predominantly 212 hydrophobic cleft created between helices on the membrane-exposed site (Fig 2a, b) . 213 Predicted polar interactions occur between the side-chains of Tyr45 and Trp48 side and 214 the carbonyl oxygen atom at the indole core (Fig 2c) . Other predicted close contacts 215 included residues experimentally defined by NMR to interact with rimantadine(24): 216 Leu20, Tyr45, Gly46, Trp48, Leu50 and Leu52, and additional interactions with Ala11, 217 Trp32 and Tyr42. Importantly, the majority of residues within this binding site are highly 218 conserved; all residues are >90% conserved with the exception of Leu20 (45.67%) and 219 Tyr45 (84.67%) (Fig 2d, S6 , Table S1 ). However, unlike rimantadine, Leu20Phe does not 220 mediate resistance to this chemical series(24). 221 JK3/32 SAR was consistent with its predicted binding pose (Fig 2e and Table 1) following 222 docking within the peripheral binding site, defining key determinants of its activity. For 223 example, substitution of the N1 position of the oxindole core demonstrated a preference 224 for benzyl substitution (e.g. JK3/32) consistent with the group occupying a relatively large longer, more hydrophobic group (N-ethylphenyl, 1191-137) , was less well tolerated.
Introduction of a NH (JK3-38), N-Ph (JK3-42) and a N-heterocyclic substituent (2, dimethylisoxazolylmethyl, 1191-106) abrogated antiviral effects. Attempts at substitution 229 at the 'northern' phenyl ring was not well tolerated, with 4-OMe (e.g. JK3/32) or H (21-230 RS-8) preferred over 4-cyano (1191-112) and 2-methoxy (1191-104) . 4-alkynyloxy was 231 only moderately less active than 4-OMe (compare 1191-146 (IC 50 2.48 μM) to 1191-140 232 (IC 50 0.46 μM)), suggesting that further synthetic expansion from this site was possible, 233 consistent with the modelling which directed this vector outwards from the binding pocket 234 into the membrane. The linker at the 3-position of the oxindole core was sensitive to 235 modification. The hydrazone analogue (21-RS-7) was much less active whilst replacement 236 of the NH for a carbonyl group (21-RS-17) was also not well tolerated. This is consistent 237 with the enamine linker adopting an important bridging unit for correct placement of the 238 N1 substituent into the deep hydrophobic pocket. Substitution of the oxindole core at the 239 5-and 6-positions with F atoms (1191-124 and 1191-121 respectively) was generally well 240 tolerated. Consistency between observed SAR and the heptameric 3ZD0-based model 241 supports that rational design based upon this system generates authentic, specific p7-242 targeted antivirals; JK3/32 SAR was not consistent with the 2M6X structure (data not 243 shown).
245
Molecular dynamics supports stable JK3/32 binding at the peripheral site. 246 We next undertook atomistic molecular dynamics simulations of genotype 1b p7 channel 247 complexes with JK3/32 bound at the peripheral site to assess the stability of interactions initially forming H-bonds with Tyr45 followed by subsequent bifurcation (after ~50 ns) 256 with Trp48 (Fig 3b) . The JK3/32 amino group made further interactions with various side 257 chains over the course of the simulation.
258
Leu20Phe mutant p7 complexes also formed a stable interaction with JK3/32 (Fig 3c) , 259 although Phe20 caused reorganisation and crowding of the binding pocket stabilized by π-260 π stacking interactions between Phe20 and Tyr45. The intramolecular H-bond between the 261 NH and carbonyl oxygen was lost on simulation, although bifurcated H-bonding to Tyr45 262 and Trp48 was maintained. We infer that efficient H-bond formation is contributory to 263 JK3/32 potency. By contrast, p7 with the Leu20Phe mutation disrupted binding of 264 rimantadine within the pocket, with the drug failing to make H-bond contacts and leaving 265 the pocket over the course of the simulation ( Fig S7) . 
HCV entry is dependent upon p7 ion channel function
We previously demonstrated a link between p7 sequence and the acid stability of secreted 269 HCV particles(18). This prompted us to speculate that, in addition to its role during 270 secretion, virion-resident channel complexes might influence virus entry. In agreement, 271 JK3/32, but not an inactive analogue from a closely related series, compound R21, 272 reduced infectivity when added to infectious genotype 1b innoculae (Fig 4a, b ). However, 273 inhibition occurred at higher JK3/32 concentrations compared to those effective against 274 virion secretion making it necessary to confirm effects were both HCV-as well as p7-275 specific. Reassuringly, the same genotype-dependent variation in JK3/32 potency was 276 evident during entry experiments as observed during secretion; genotype 3a chimaeric 277 viruses required 2-4 fold higher concentration than genotype 1b and R21 again had no 278 effect (Fig 4c) . As expected, compounds displayed no evidence of cytotoxicity at higher 279 concentrations ( Fig S8a, b) . Note, JFH-1 was not employed during these experiments as 280 R21 displayed modest but significant inhibitory activity against this strain in both 281 secretory and entry assays, preventing its use as a negative control. 282 Multiple unsuccessful attempts were made to select resistance to JK3/32 in culture (data 283 not shown), meaning that it was not possible to provide genetic evidence supporting 284 interactions with this compound during virus entry. We infer that this is due to the high 285 degree of conservation seen within the JK3/32 binding site (Fig 2d) . However, we 286 previously defined both strain-and polymorphism-dependent resistance to prototypic 287 adamantane and alkyl imino-sugar p7i(23), providing a means to assess p7 target 288 engagement during entry. Secretion of genotype 2a JFH-1 HCV is innately amantadine- 289 resistant, yet remains sensitive to rimantadine and the alkyl imino-sugar NN-DNJ. Virus 290 entry experiments recapitulated this pattern, with the latter two compounds displaying 291 dose-dependent efficacy (Fig 4d) . Moreover, entry of JFH-1 Leu20Phe was resistant to 292 both amantadine and rimantadine, whilst remaining NN-DNJ-sensitive; NN-DNJ disrupts 293 p7 oligomerisation rather than binding peripherally(23). Hence, p7 sequence dictated p7i-294 mediated blockade of HCV entry, providing genetic evidence for virion-resident channels. 295 Consistently, JK3/32 only blocked infection when introduced during virus infection, 296 concordant with a direct effect upon virion-resident channels, whereas the NS5Ai 297 Daclatasvir only interfered with HCV infection when added post-entry (Fig 4e) . 298 Next, we used Lentiviral vectors pseudotyped with HCV glycoproteins to establish 299 whether JK3/32 effects were p7-specific, or might instead interfere with receptor binding, 300 particle integrity or membrane fusion. Encouragingly, neither JK3/32 nor R21 had effects 301 upon the entry of pseudotypes possessing patient-derived E1/E2 representing genotype 1b 302 or 3a(38), whereas Galanthus nivalis Agglutinin (GNA) blocked entry in a dose-303 dependent fashion (Fig 4f) . Pseudotypes based upon prototypic genotype 1a or 2a, as well 304 as the vesicular stomatitis virus glycoprotein (VSV-G) control, were also unaffected by 305 JK3/32 or R21 ( Fig S8c) . 306 Lastly, to discern whether JK3/32 affected clathrin-mediated endocytosis, we tested 307 sensitivity of pandemic H1N1 IAV entry to the compound. Not only does IAV enter cells 308 via this pathway, it also retains virion-associated M2 viroporin proton channels thereby 309 serving as an additional control for JK3/32 specificity. Accordingly, JK3/32 did not affect 310 IAV entry (Fig 4g) . In addition, JK3/32 did not interfere with clathrin-dependent uptake of 311 fluorescent-tagged epidermal growth factor (EGF) (Fig 4h, S8d) . Taken together, evidence 312 supports that JK3/32 inhibits HCV entry in a p7 sequence-, genotype-, and temporally-313 dependent fashion, with no appreciable effects upon cellular endocytic pathways. Purified genotype 1b chimaeric HCV, dosed with 10 μM JK3/32, JK3/32-488, R21 or 328 DMSO, was separated from unbound ligand by centrifugation through continuous 329 iodixinol density gradients. Both control and R21-exposed gradients yielded overlapping 330 peaks of infectivity at densities between 1.1 and 1.15 g/mL (corresponding to fractions 4-7 331 of the gradient), consistent with previous studies (Fig 5a, b, S9 ). However, infectivity was 332 effectively abrogated in peak fractions treated with either JK3/32 or JK3/32-488, although 333 a small number of infected cells were detectable (Fig 5a, b, S9 ). Quantification of the 334 fluorescent signal from JK3/32-488 revealed concentrations within peak infectivity 335 fractions were <2 nM (fractions 5 & 6). Hence, separation of treated virions from unbound 336 compound using this method resulted in cellular exposure to far lower concentrations than 337 those able to block HCV secretion, making off-target effects extremely unlikely (Fig 5c) . 338 Importantly, neither JK3/32 nor JK3/32-488 affected the stability of HCV particles as 339 migration of virion-associated core protein corresponded with the peak of infectivity in 340 each case, and was identical to the R21 control ( Fig 5d) . Hence, we conclude that effects 341 upon HCV entry are not attributable to cellular exposure to JK3/32, and that the 342 compound irreversibly blocks virion-resident p7 channels. targeting two discrete stages of the virus life cycle. Hence, this work sets a new precedent for viroporin-targeted drug development that should enable the field to advance beyond amantadine-and/or rimantadine-based influenza therapy. 360 The potency and selectivity demonstrated by JK3/32 was consistent with comprehensive 361 SAR, docking predictions within the peripheral binding site, as well as MD simulations of 362 the bound JK3/32 ligand over time. Each binding site occurs between adjacent hairpin-363 formation protomers and the majority of residues are highly conserved (Fig 2c, d) . This 364 includes Tyr45 and Trp48, which form key H-bond interactions with the JK3/32 indole 365 carbonyl. Only Leu20 (~46% conserved) shows appreciable variation within the binding 366 site, with the rimantadine-resistant Phe20 occurring in just ~3.6% of isolates in the EU 367 HCV database (Fig 2d, Table S1 ); Val (~30%) or Ala (~12%) are more common. 368 Moreover, Phe20 stabilises rather than disrupts interactions with JK3/32 during MD 369 simulations, and JK3/32-related compounds are unaffected by this mutation in culture(24). 370 We infer that the high degree of conservation within this site explains why JK3/32 specific 371 resistance was not selectable in culture, despite several attempts. 372 Interestingly, the genotype 5a (EUH1480 isolate) 2M6X channel complex solution 373 structure, comprising triple-helix protomers, contains Phe20 within a peripheral 374 adamantane binding site(29); this site differs significantly in amino acid composition and 375 structure compared to the 3ZD0-based hairpin heptamer model. Unfortunately, the 376 recombinant protein used for structure determination did not display ion channel activity, 377 making it impossible to determine drug sensitivity(29). Nevertheless, a related genotype 378 5a (SA-13) also retains Phe20 and is rimantadine-sensitive in culture(37), supporting that 379 Phe20 mediated rimantadine resistance is context-specific. The EUH1480 p7 sequence 380 was modified to enhance recombinant expression, primarily at Cys residues. Amongst 381 these, Cys2 is only found within GT5a (present in just 0.07% of p7 sequences overall, see 382 Table S1 ), and Cys27 is highly conserved across all genotypes (>95%). It is conceivable 383 that these mutations were responsible for the lack of observable channel activity for this 384 protein. 385 Unlike the peripheral rimantadine binding site in 3ZD0-based models, the region bound by 386 amantadine in the 2M6X complex(29), comprising Phe20, Val25, Val26, Leu52, Val53, 387 Leu55 and Leu56, is poorly conserved (Table S1 ). Only Leu52 and Leu55 represent 388 consensus residues at their respective positions, with all the others being minority species. 389 Moreover, three of the seven residues vary between the closely related SA-13 and 390 EUH1480 genotype 5a strains (positions 26, 53 and 55). Unsurprisingly, JK3/32 binding 391 and SAR is incompatible with this site within the 2M6X complex, or more importantly, 392 with a genotype 1b homology model based upon the 2M6X structure (data not shown). 393 Taken together, our findings add to the NMR-specific concerns recently raised regarding 394 2M6X(30) and support that biologically functional p7 channels comprise arrangements of 395 hairpin protomers. 396 JK3/32 was compared to a patented p7i advanced into early phase human studies in South 397 East Asia, BIT225(36) (N-Carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide, 398 Biotron Ltd, Australia). BIT225 is an amiloride-related compound selected as an inhibitor 399 of genotype 1a p7 (H77 strain) from a bacterial screen, with activity against recombinant 400 protein at 100 μM in suspended bilayers. As a surrogate for HCV in culture, BIT225 401 potently inhibited replication of the Pestivirus, bovine viral diarrhoea virus (BVDV) (IC 50 402 314 nM), although specificity was not attributed to the BVDV p7 protein(36). However, 403 BIT225 later showed genotype-dependent efficacy versus HCV(37), with IC 50 values of 404 10 μM or 30 μM (genotype 2a and 5a chimaeric HCV, respectively); interestingly, these concentrations are far higher than those effective versus BVDV(36). Whilst we observed a 406 similar anti-HCV IC 50 of 17.7 μM versus genotype 1b chimaeric HCV, this coincided with 407 the CC 50 of 18.6 μM ( Fig S5) , making it impossible to define a selective antiviral effect. 408 Notably, Huh7 cell cytotoxicity was not determined in previous HCV studies(37), whereas 409 BVDV studies reported a CC 50 of 11.6 μM for Madin-Darby bovine kidney (MDBK) 410 cells, with appreciable (~16%) cytotoxicity at just 4 μM(36). We conclude that BIT225 411 may show greater potency versus BVDV than HCV, and that selective antiviral effects 412 cannot be determined for HCV in the Huh7 system. This contrasts with the considerable 413 selectivity index observed for JK3/32 (>500, Fig S2) . 414 JK3/32 inhibition of secreted HCV infectivity showed cross-genotypic potency, including 415 versus genotype 3a, which can be more difficult to treat using current DAAs (Fig 1b, c) . 416 Thus, we were naturally cautious regarding the higher concentrations required to block 417 HCV entry, although this effect was reproducible compared to the inactive R21 analogue, 418 showed genotype-dependent variation and was coincident with entry ( Fig 4a-c, e ). 419 Lentiviral pseudotype assays supported that JK3/32 did not affect E1/E2 mediated 420 receptor binding or membrane fusion (Fig 4f, S8c) , plus it did not affect IAV entry or 421 clathrin-mediated endocytosis (Fig 4g, h) . Moreover, strain/polymorphism-dependent 422 resistance to prototypic p7i provided genetic evidence of target engagement (Fig 4d) and 423 we were effectively able to rule out cell-dependent effects using our fluorescent-tagged 424 JK3/32 derivative ( Fig 5) , supporting irreversible dosing of virion-resident p7 channels. 425 We speculate that the different biological roles of p7 channel activity during secretion and 426 entry may explain why higher p7i concentrations are required to block the latter process. 427 During secretion, p7 must counteract active proton gradients generated by vATPase in (19, 20) . These observations suggest that supplementing 447 p7 function during virion secretion is sufficient to restore infectivity, negating the 448 requirement for p7 to act during entry. 449 However, this interpretation assumes that basic loop mutations specifically affect ion 450 channel activity in isolation, yet no published evidence exists to support this notion. 451 Instead, basic loop mutations induce defects in p7 stability and E2-p7-NS2 precursor processing within infected cells (19), as well as severe disruption of membrane insertion 453 observed in vitro (39) . It is likely that cell phenotypes directly link to defective membrane 454 insertion, suggesting that p7 may spontaneously insert into membranes rather than 455 depending upon the signal recognition particle. Spontaneous membrane insertion would particles by allowing them to survive within acidifying vesicles, which could then proceed 466 to infect naïve cells. 467 One limitation of our study is the absence of p7 immunological detection within purified 468 HCV virions. We previously generated the only published p7-specific polyclonal antisera, 469 which required extensive concentration to detect relatively high protein 470 concentrations(39). Nevertheless, these are the only reagents described for the detection of 471 native p7 protein, as confirmed by others(8, 10). Whilst we applied these reagents to 472 virion detection, stocks expired prior to a conclusive outcome. Others used recombinant 473 viruses expressing epitope tagged p7 to investigate the presence of channel complexes 474 within virions by co-immunoprecipitation(42). However, whilst p7 was not detectable 475 within either anti-ApoE or Anti-E2 precipitates, the levels of core protein present were 476 also low; by analogy with M2, we expect p7 to be present in stoichiometrically low 477 numbers compared with canonical virion components. Similarly, p7 was not detected by 478 mass spectrometry (MS) conducted upon affinity-purified HCV particles(43), yet this was 479 also true for the E1 glycoprotein, which should show equivalent abundance to E2 resulting 480 from heterodimer formation. 481 Thus, poor reagent quality combined with low protein abundance hampers direct detection 482 of p7 within virions, representing a significant challenge that we intend to address by the 483 addition of an affinity tag to the "click"-labelled JK3/32 derivative. Concentration of 484 virions and signal amplification will be essential as gradient infectivity peaks have an 485 approximate particle molarity of 0.5 fM, based upon infectivity measurements (Figure 5a ). 486 IAV particles contain only 16-20 M2 proteins(44), meaning that even a high particle: In summary, viroporins represent an untapped reservoir of antiviral drug targets that has 503 historically been under-explored following the shortcomings of adamantane M2 inhibitors. 504 Our work shows that it is possible to take a step-change in targeting these proteins, 505 providing a new approach to antiviral therapy and generating novel research tools with 506 which to dissect viroporin function. 507 508
Materials and Methods
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Materials and Methods
512
Virus secretion inhibition assays 513 Huh7 cells were cultured and propagated as described previously (21). Secreted infectivity 514 was measured as described (34) 
EGF uptake assay
Huh7 cells were seeded into 24-well plates (1.5x10 5 per well) and left to adhere for ~6 h. 651 Cells were then treated using titrated compounds or Bafilomycin A (1μM) as a positive 652 control for 4 h. Cells were then washed extensively and media replaced with PBS 653 containing 2 μgμL -1 FITC-conjugated epidermal growth factor (EGF, Invitrogen) for 30 654 min. Cells were then washed extensively, removed using a cell scraper and then fixed in 4 655 % (w/v) paraformaldehyde in PBS for 10 min at room temperature. Flow cytometry was 656 then used to determine median FITC levels, with gating on intact cells. All conditions 657 were performed in triplicate. (Table S1 , Fig S6) . Data was exported into 673 MS Excel, then inputted into a free sequence logo website (https://weblogo.berkeley.edu/) 674 to visualise relative occupancy (Fig 2d) . Generation of optimised heptameric 3ZD0-based p7 channel structure 684 The initial heptameric channel model was constructed using the Maestro programme 685 (Schrödinger) based upon the monomeric unit from the 3ZD0 NMR structure as 686 described(24). A heptameric bundle arrangement of protomers was oriented with His17 687 oriented towards the lumen equidistant from a centroid atom placed in the middle of the 688 lumen to serve as a rotational centre with multiple energy minimisation steps. Iterative 689 rotation of protomers in an octanol environment generated solutions. The preferred model 690 was then refined using molecular dynamics simulations (methods described below). Ligands were prepared using MOE software. Hydrogens atoms were added using the 700 protonate 3D option and then partial charges were assigned with MMFF94 force field 701 default parameters. Energy minimizations were performed using MMFF94 force field with 702 a root mean square gradient of 0.1 kcal Mol -1 .Å -1 and gas phase solvation model. 703 For docking, Leu20 or Phe20 residues were selected from each monomer of the wild type 704 and mutated proteins respectively. Receptor sites with a radius of 5 Å is defined around Anti-NS5A Top Bottom
